Suchergebnisse - "Markowski, Mark C"

PubPharm (13)

1

Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer

enthalten in: The Prostate | 2024

von Marshall, C. | Gondek, L. | Daniels, V. | +9

2

Test-retest repeatability of organ uptake on PSMA-targeted 18 F-DCFPyL PET/CT in patients with prostate cancer

enthalten in: The Prostate | 2023

von Werner, R. | Lütje, S. | Habacha, B. | +14

3

Bipolar Androgen Therapy Followed by Androgen Receptor Inhibition as Sequential Therapy for Prostate Cancer

enthalten in: The oncologist | 2023

von Denmeade, S. | Sena, L. | Wang, H. | +2

4

Lack of repeatability of radiomic features derived from PET scans : Results from a 18 F-DCFPyL test-retest cohort

enthalten in: The Prostate | 2023

von Werner, R. | Habacha, B. | Lütje, S. | +16

5

Role of bromodomain and extraterminal (BET) proteins in prostate cancer

enthalten in: Expert opinion on investigational drugs | 2023

von Mandl, A. | Markowski, M. | Carducci, M. | +1

6

The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

enthalten in: Journal of nuclear medicine : official publication, Society of Nuclear Medicine | 2022

von Dong, L. | Su, Y. | Zhu, Y. | +10

7

PARP inhibitors in prostate cancer : time to narrow patient selection?

enthalten in: Expert review of anticancer therapy | 2020

von Markowski, M. | Antonarakis, E.

8

Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancer

enthalten in: The Prostate | 2020

von Markowski, M. | Shenderov, E. | Eisenberger, M. | +4

9

Characterization of novel cell lines derived from a MYC-driven murine model of lethal metastatic adenocarcinoma of the prostate

enthalten in: The Prostate | 2018

von Markowski, M. | Hubbard, G. | Hicks, J. | +7

10

BET inhibitors in metastatic prostate cancer : therapeutic implications and rational drug combinations

enthalten in: Expert opinion on investigational drugs | 2017

von Markowski, M. | De Marzo, A. | Antonarakis, E.